Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19
Indian Journal of Critical Care Medicine2022Vol. 26(6), pp. 696–703
Citations Over Time
Ashish Jain, Rohit Jain, Rajeev Kasliwal, Priyamvada Gupta, Anand Jain, Divyansh Gupta, Srishti Jain, Rohan Tambi, Puneet Panwar, Munesh Meena, Ravi Jain
Abstract
Jain A, Kasliwal R, Jain SS, Jain R, Gupta D, Gupta P, et al. Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19. Indian J Crit Care Med 2022;26(6):696-703.
Related Papers
- → Early Enteral Nutrition and Outcomes of Critically Ill Patients Treated With Vasopressors and Mechanical Ventilation(2010)305 cited
- → Tracheostomy does not improve the outcome of patients requiring prolonged mechanical ventilation: A propensity analysis*(2006)150 cited
- → Ulinastatin did not reduce mortality in elderly multiple organ failure patients: a retrospective observational study in a single center ICU(2017)11 cited
- → Characteristics and outcomes of surgical patients admitted to an overnight intensive recovery unit: A retrospective observational study(2022)6 cited
- → Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19(2022)4 cited